Spouse Penny Hall Fields Cancer | Name Tony Kouzarides | |
 | ||
Born 17 January 1958 (age 66) ( 1958-01-17 ) Institutions University of LeedsUniversity of CambridgeGurdon InstituteNew York UniversityLaboratory of Molecular BiologyAbcam Thesis A molecular analysis of transformation by human cytomegalovirus (1985) Doctoral students Jacqui SutherlandHelen BrownJuliet Reid Klaus MartinEric MiskaPhilip ZegermanWendy BergersDan WolfGraeme CuthbertKaren HallsClaire Pike Other notable students (postdocs)Christian HagemeierDidier TroucheJonathan MilnerAlex BrehmCatherine Le ChalonySoren NeilsonPaul LavenderFrancois FuksMarian Martinez BalbasLaurence VandelUta-Maria BauerGuida RuasEmma LangleySylvain DaujatLuke Hughes-DaviesRobert SchneiderSteve SandersSusana LopesChris NelsonPaul HurdSopie DeltourDavid LandoAntonis KirmizisHatice AkarsuBlerta XhemalceTill BartkeMarc SchneiderGoncalo Castelo-Branco Notable awards Heinrich Wieland Prize, Royal Society, Academy of Medical Sciences, United Kingdom | ||
Tony kouzarides director de la fundaci n vencer el c ncer
Tony Kouzarides, FMedSci, FRS (born 17 January 1958) is the deputy director of the Gurdon Institute, a founding non-executive director of Abcam and a Professor of Cancer Biology at the University of Cambridge.
Contents
- Tony kouzarides director de la fundaci n vencer el c ncer
- Epigenetic modifications their function and role in cancer tony kouzarides
- Education
- Research
- Awards
- References
Epigenetic modifications their function and role in cancer tony kouzarides
Education
Kouzarides was educated at the University of Leeds, graduating with a Bachelor of Science degree in Genetics in 1981. He went on to complete his PhD at the University of Cambridge in 1985.
Research
Following his PhD, Kouzarides did postdoctoral work at the Laboratory of Molecular Biology (LMB) on the cancer potential of cytomegalovirus. and then on to New York University Medical Center. Here he examined the c-Fos leucine zipper dimerisation domain to elucidate its function. He got a job at the Gurdon Institute in Cambridge, where he has been since.
Kouzarides is a leader in the field of chromatin modification and its role in transcriptional control and cancer. In 1996 he made a key discovery in finding that the transcriptional co-activator CBP is a histone acetyltransferase. He has since worked on identifying several new histone modifications, describing their functions in transcription and DNA repair and highlighting their mis-regulation in cancer. His demonstration that a histone acetylation pathway inhibitor can be used to treat MLL-leukaemias has facilitated its use in clinical trials.
Awards
Kouzarides was elected a member of the Academy of Medical Sciences (FMedSci) in 2001. He received the Bijvoet Medal of the Bijvoet Center for Biomolecular Research of Utrecht University in 2008. He was elected a Fellow of the Royal Society (FRS) in 2012. His nomination read:
"Tony Kouzarides is world leader in the field of chromatin modification and its roles in transcriptional control and cancer. His finding in 1996 that the transcriptional co-activator CBP is a histone acetyltransferase was one of the key discoveries that started the modern era of chromatin research. His subsequent work has identified several new histone modifications, described their functions in transcription and DNA repair and has highlighted their mis-regulation in cancer. His demonstration that a histone acetylation pathway inhibitor is an effective treatment for MLL-leukaemias in disease models has opened the way to its use in clinical trials."
Kouzarides was also awarded the Sanofi-Cell Research Outstanding Paper Award of 2011 for his paper on Regulation of chromatin by histone modifications co-authored with Andrew Bannister.
In 2013, he was awarded the Heinrich Wieland Prize for his pioneering "research on gene regulation and cancer"